CohBar, Inc. (NASDAQ:CWBR) is reporting second quarter earnings results on Thursday 13th August 2020, after market close.
Previous Quarter Performance
CohBar, Inc. posted loss for the first quarter of $ 0.10 per share, from the revenue of . The quarterly revenues compared with the same quarter last year. According to street consensus, revenue of was expected for the first quarter The bottom line results street analysts by $ 0.08 or , at the same time, top line results analysts by $ 0.23 million or .
Stock Performance
According to the previous trading day, closing price of CWBR was $ 1.55, representing a 78.16 % increase from the 52 week low of $ 0.87 and a 63.53 % decrease over the 52 week high of $ 4.25.
The company has a market capital of $ 66.92 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CWBR” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of diseases associated with aging and metabolic dysfunction. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular disease, and neurodegenerative disease, such as Alzheimers disease. Its lead MBT candidate is CB4211, a novel optimized analog of the MOTS-c mitochondrial-derived peptide for the treatment of NASH and obesity.
